Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays.

Blevins TP, Yu Y, Belshe RB, Bellamy AR, Morrison LA.

PLoS One. 2019 Apr 4;14(4):e0214467. doi: 10.1371/journal.pone.0214467. eCollection 2019.

2.

Molecular analyses and phylogeny of the herpes simplex virus 2 US9 and glycoproteins gE/gI obtained from infected subjects during the Herpevac Trial for Women.

Rowe KL, Minaya MA, Belshe RB, Morrison LA.

PLoS One. 2019 Mar 8;14(3):e0212877. doi: 10.1371/journal.pone.0212877. eCollection 2019.

3.

The Potential of LAIV for the Prevention of Influenza in Children.

Belshe RB.

Clin Infect Dis. 2018 Nov 27. doi: 10.1093/cid/ciy1007. [Epub ahead of print] No abstract available.

PMID:
30517601
4.

Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats.

Joyce C, Scallan CD, Mateo R, Belshe RB, Tucker SN, Moore AC.

Vaccine. 2018 Jul 5;36(29):4265-4277. doi: 10.1016/j.vaccine.2018.05.112. Epub 2018 Jun 9.

PMID:
29895499
5.

A phase I safety and immunogenicity dose escalation trial of plague vaccine, Flagellin/F1/V, in healthy adult volunteers (DMID 08-0066).

Frey SE, Lottenbach K, Graham I, Anderson E, Bajwa K, May RC, Mizel SB, Graff A, Belshe RB.

Vaccine. 2017 Dec 4;35(48 Pt B):6759-6765. doi: 10.1016/j.vaccine.2017.09.070. Epub 2017 Oct 14.

PMID:
29037578
6.

Molecular Evolution of Herpes Simplex Virus 2 Complete Genomes: Comparison between Primary and Recurrent Infections.

Minaya MA, Jensen TL, Goll JB, Korom M, Datla SH, Belshe RB, Morrison LA.

J Virol. 2017 Nov 14;91(23). pii: e00942-17. doi: 10.1128/JVI.00942-17. Print 2017 Dec 1.

7.

The herpevac trial for women: Sequence analysis of glycoproteins from viruses obtained from infected subjects.

Minaya MA, Korom M, Wang H, Belshe RB, Morrison LA.

PLoS One. 2017 Apr 27;12(4):e0176687. doi: 10.1371/journal.pone.0176687. eCollection 2017.

8.

Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults.

Hoft DF, Lottenbach KR, Blazevic A, Turan A, Blevins TP, Pacatte TP, Yu Y, Mitchell MC, Hoft SG, Belshe RB.

Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00414-16. doi: 10.1128/CVI.00414-16. Print 2017 Jan.

9.

Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.

Hoft DF, Lottenbach K, Goll JB, Hill H, Winokur PL, Patel SM, Brady RC, Chen WH, Edwards K, Creech CB, Frey SE, Blevins TP, Salomon R, Belshe RB.

J Infect Dis. 2016 Oct 1;214(7):1020-9. doi: 10.1093/infdis/jiw310. Epub 2016 Jul 20.

10.

Development of a high-throughput β-Gal-based neutralization assay for quantitation of herpes simplex virus-neutralizing antibodies in human samples.

Baccari A, Cooney M, Blevins TP, Morrison LA, Larson S, Skoberne M, Belshe RB, Flechtner JB, Long D.

Vaccine. 2016 Jul 19;34(33):3901-6. doi: 10.1016/j.vaccine.2016.05.033. Epub 2016 Jun 15.

PMID:
27265458
11.

A systematic review of the efficacy of live attenuated influenza vaccine upon revaccination of children.

Caspard H, Heikkinen T, Belshe RB, Ambrose CS.

Hum Vaccin Immunother. 2016 Jul 2;12(7):1721-7. doi: 10.1080/21645515.2015.1115164. Review.

12.

Higher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses.

Blevins TP, Mitchell MC, Korom M, Wang H, Yu Y, Morrison LA, Belshe RB.

PLoS One. 2015 Dec 14;10(12):e0144738. doi: 10.1371/journal.pone.0144738. eCollection 2015.

13.

Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.

Mbawuike IN, Atmar RL, Patel SM, Corry DB, Winokur PL, Brady RC, Chen WH, Edwards KM, Creech CB, Walter EB Jr, Frey SE, Belshe RB, Goll JB, Hill H, Keitel WA.

Vaccine. 2016 Jan 20;34(4):547-554. doi: 10.1016/j.vaccine.2015.11.055. Epub 2015 Dec 4.

14.

Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.

Frey SE, Wald A, Edupuganti S, Jackson LA, Stapleton JT, El Sahly H, El-Kamary SS, Edwards K, Keyserling H, Winokur P, Keitel W, Hill H, Goll JB, Anderson EL, Graham IL, Johnston C, Mulligan M, Rouphael N, Atmar R, Patel S, Chen W, Kotloff K, Creech CB, Chaplin P, Belshe RB.

Vaccine. 2015 Sep 22;33(39):5225-34. doi: 10.1016/j.vaccine.2015.06.075. Epub 2015 Jul 2.

PMID:
26143613
15.

Aging-dependent alterations in gene expression and a mitochondrial signature of responsiveness to human influenza vaccination.

Thakar J, Mohanty S, West AP, Joshi SR, Ueda I, Wilson J, Meng H, Blevins TP, Tsang S, Trentalange M, Siconolfi B, Park K, Gill TM, Belshe RB, Kaech SM, Shadel GS, Kleinstein SH, Shaw AC.

Aging (Albany NY). 2015 Jan;7(1):38-52.

16.

Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.

Frey SE, Bernstein DI, Brady RC, Keitel WA, El Sahly H, Rouphael NG, Mulligan MJ, Atmar RL, Edupuganti S, Patel SM, Dickey M, Graham I, Anderson EL, Noah DL, Hill H, Wolff M, Belshe RB.

Vaccine. 2015 Jan 1;33(1):163-73. doi: 10.1016/j.vaccine.2014.10.083. Epub 2014 Nov 11.

17.

Prolonged proinflammatory cytokine production in monocytes modulated by interleukin 10 after influenza vaccination in older adults.

Mohanty S, Joshi SR, Ueda I, Wilson J, Blevins TP, Siconolfi B, Meng H, Devine L, Raddassi K, Tsang S, Belshe RB, Hafler DA, Kaech SM, Kleinstein SH, Trentalange M, Allore HG, Shaw AC.

J Infect Dis. 2015 Apr 1;211(7):1174-84. doi: 10.1093/infdis/jiu573. Epub 2014 Nov 2.

18.

Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.

Belshe RB, Frey SE, Graham IL, Anderson EL, Jackson LA, Spearman P, Edupuganti S, Mulligan MJ, Rouphael N, Winokur P, Dolor RJ, Woods CW, Walter EB, Chen WH, Turley C, Edwards KM, Creech CB, Hill H, Bellamy AR; National Institute of Allergy and Infectious Diseases–Funded Vaccine and Treatment Evaluation Units.

JAMA. 2014 Oct 8;312(14):1420-8. doi: 10.1001/jama.2014.12609.

PMID:
25291578
19.

Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.

Wong JA, Bhat R, Hockman D, Logan M, Chen C, Levin A, Frey SE, Belshe RB, Tyrrell DL, Law JL, Houghton M.

J Virol. 2014 Dec;88(24):14278-88. doi: 10.1128/JVI.01911-14. Epub 2014 Oct 1.

20.

Progress toward the development of universal influenza vaccines.

Hoft DF, Belshe RB.

Mo Med. 2014 Jul-Aug;111(4):321-5.

21.

Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity.

Ambrose CS, Wu X, Caspard H, Belshe RB.

Vaccine. 2014 Sep 29;32(43):5546-8. doi: 10.1016/j.vaccine.2014.07.097. Epub 2014 Aug 12.

22.

HSV-1 and HSV-2 seroprevalence in the united states among asymptomatic women unaware of any herpes simplex virus infection (Herpevac Trial for Women).

Schulte JM, Bellamy AR, Hook EW 3rd, Bernstein DI, Levin MJ, Leone PA, Sokol-Anderson ML, Ewell MG, Wolff PA, Heineman TC, Belshe RB.

South Med J. 2014 Feb;107(2):79-84. doi: 10.1097/SMJ.0000000000000062.

PMID:
24926671
23.

No clinical association of live attenuated influenza virus with nasal carriage of bacteria or acute otitis media.

Coelingh KL, Belshe RB.

MBio. 2014 May 13;5(3):e01145-14. doi: 10.1128/mBio.01145-14. No abstract available.

24.

Repertoire of epitopes recognized by serum IgG from humans vaccinated with herpes simplex virus 2 glycoprotein D.

Whitbeck JC, Huang ZY, Cairns TM, Gallagher JR, Lou H, Ponce-de-Leon M, Belshe RB, Eisenberg RJ, Cohen GH.

J Virol. 2014 Jul;88(14):7786-95. doi: 10.1128/JVI.00544-14. Epub 2014 Apr 30.

25.

Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.

Awasthi S, Belshe RB, Friedman HM.

J Infect Dis. 2014 Aug 15;210(4):571-5. doi: 10.1093/infdis/jiu177. Epub 2014 Mar 20.

26.

Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.

Frey SE, Winokur PL, Hill H, Goll JB, Chaplin P, Belshe RB.

Vaccine. 2014 May 13;32(23):2732-9. doi: 10.1016/j.vaccine.2014.02.043. Epub 2014 Mar 6.

27.

Correlate of immune protection against HSV-1 genital disease in vaccinated women.

Belshe RB, Heineman TC, Bernstein DI, Bellamy AR, Ewell M, van der Most R, Deal CD.

J Infect Dis. 2014 Mar;209(6):828-36. doi: 10.1093/infdis/jit651. Epub 2013 Nov 27.

28.

Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses.

Medina RA, Stertz S, Manicassamy B, Zimmermann P, Sun X, Albrecht RA, Uusi-Kerttula H, Zagordi O, Belshe RB, Frey SE, Tumpey TM, García-Sastre A.

Sci Transl Med. 2013 May 29;5(187):187ra70. doi: 10.1126/scitranslmed.3005996.

29.

Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.

Frey SE, Winokur PL, Salata RA, El-Kamary SS, Turley CB, Walter EB Jr, Hay CM, Newman FK, Hill HR, Zhang Y, Chaplin P, Tary-Lehmann M, Belshe RB.

Vaccine. 2013 Jun 24;31(29):3025-33. doi: 10.1016/j.vaccine.2013.04.050. Epub 2013 May 9.

30.

An altered relationship of influenza vaccine-specific IgG responses with T cell immunity occurs with aging in humans.

Kang KS, Lee N, Shin MS, Kim SD, Yu Y, Mohanty S, Belshe RB, Montgomery RR, Shaw AC, Kang I.

Clin Immunol. 2013 May;147(2):79-88. doi: 10.1016/j.clim.2013.02.022. Epub 2013 Mar 15.

31.

A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans.

Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, Belshe RB, Wakita T, Bukh J, Jones CT, Rice CM, Abrignani S, Tyrrell DL, Houghton M.

PLoS One. 2013;8(3):e59776. doi: 10.1371/journal.pone.0059776. Epub 2013 Mar 19.

32.

Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.

Toback SL, Levin MJ, Block SL, Belshe RB, Ambrose CS, Falloon J.

Expert Rev Vaccines. 2012 Nov;11(11):1293-303. doi: 10.1586/erv.12.108. Epub 2012 Nov 14. Review.

PMID:
23151111
33.

Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women.

Bernstein DI, Bellamy AR, Hook EW 3rd, Levin MJ, Wald A, Ewell MG, Wolff PA, Deal CD, Heineman TC, Dubin G, Belshe RB.

Clin Infect Dis. 2013 Feb;56(3):344-51. doi: 10.1093/cid/cis891. Epub 2012 Oct 19.

34.

Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.

Frey SE, Bernstein DI, Gerber MA, Keyserling HL, Munoz FM, Winokur PL, Turley CB, Rupp RE, Hill H, Wolff M, Noah DL, Ross AC, Cress G, Belshe RB.

J Infect Dis. 2012 Sep 15;206(6):828-37. doi: 10.1093/infdis/jis445. Epub 2012 Jul 16.

35.

A century of influenza prevention in St. Louis.

Belshe RB.

Mo Med. 2012 Mar-Apr;109(2):119-23.

36.

Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.

Hughes CM, Newman FK, Davidson WB, Olson VA, Smith SK, Holman RC, Yan L, Frey SE, Belshe RB, Karem KL, Damon IK.

Clin Vaccine Immunol. 2012 Jul;19(7):1116-8. doi: 10.1128/CVI.00056-12. Epub 2012 May 16.

37.

Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children.

Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, Belshe RB.

Pediatr Infect Dis J. 2012 Jul;31(7):745-51. doi: 10.1097/INF.0b013e31825687b0.

PMID:
22466322
38.

The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing.

Ambrose CS, Dubovsky F, Yi T, Belshe RB, Ashkenazi S.

Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2549-57. Epub 2012 Mar 14.

39.

Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses.

Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, Banach D, Wrammert J, Belshe RB, García-Sastre A, Palese P.

Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2573-8. doi: 10.1073/pnas.1200039109. Epub 2012 Jan 30.

40.

Influenza vaccine in young children.

Ambrose CS, Belshe RB.

N Engl J Med. 2012 Jan 26;366(4):383; author reply 383-4. doi: 10.1056/NEJMc1113381. No abstract available.

PMID:
22276839
41.

Efficacy results of a trial of a herpes simplex vaccine.

Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow RL, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CD; Herpevac Trial for Women.

N Engl J Med. 2012 Jan 5;366(1):34-43. doi: 10.1056/NEJMoa1103151.

42.

A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection.

Meyer K, Banerjee A, Frey SE, Belshe RB, Ray R.

PLoS One. 2011;6(8):e23699. doi: 10.1371/journal.pone.0023699. Epub 2011 Aug 22.

43.

Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children.

Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB, Gerber MA, Bernstein DI, Newman F, Graham I, Anderson EL, Belshe RB.

J Infect Dis. 2011 Sep 15;204(6):845-53. doi: 10.1093/infdis/jir436. Epub 2011 Aug 15.

44.

The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults.

Ambrose CS, Levin MJ, Belshe RB.

Influenza Other Respir Viruses. 2011 Mar;5(2):67-75. doi: 10.1111/j.1750-2659.2010.00183.x. Epub 2010 Nov 19. Review.

45.

Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.

Belshe RB, Frey SE, Graham I, Mulligan MJ, Edupuganti S, Jackson LA, Wald A, Poland G, Jacobson R, Keyserling HL, Spearman P, Hill H, Wolff M; National Institute of Allergy and Infectious Diseases-Funded Vaccine and Treatment Evaluation Units.

J Infect Dis. 2011 Mar 1;203(5):666-73. doi: 10.1093/infdis/jiq093. Epub 2011 Jan 31.

46.

Benefits and risks of live attenuated influenza vaccine in young children.

Oster G, Weycker D, Edelsberg J, Nichol KL, Klein JO, Belshe RB.

Am J Manag Care. 2010 Sep;16(9):e235-44.

PMID:
21250400
47.

Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus.

Medina RA, Manicassamy B, Stertz S, Seibert CW, Hai R, Belshe RB, Frey SE, Basler CF, Palese P, García-Sastre A.

Nat Commun. 2010 Jun 15;1:28. doi: 10.1038/ncomms1026.

48.

The need for quadrivalent vaccine against seasonal influenza.

Belshe RB.

Vaccine. 2010 Sep 7;28 Suppl 4:D45-53. doi: 10.1016/j.vaccine.2010.08.028. Review.

PMID:
20713260
49.

Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.

Ray R, Meyer K, Banerjee A, Basu A, Coates S, Abrignani S, Houghton M, Frey SE, Belshe RB.

J Infect Dis. 2010 Sep 15;202(6):862-6. doi: 10.1086/655902.

50.

Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.

Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB.

Vaccine. 2010 Aug 31;28(38):6367-73. doi: 10.1016/j.vaccine.2010.06.084. Epub 2010 Jul 7.

Supplemental Content

Loading ...
Support Center